Cholesteryl Ester Transfer Protein Inhibitory Activity of New 4-Bromophenethyl Benzamides

Cardiovascular diseases, as coronary heart disease, failure, and hypertension are the first leading cause of death in United States third globally. CETP is a glycoprotein excreted mainly from liver found plasma. Normal plasma concentration 1-4 µg/ml, while ratio increased 70-80% dyslipidemic patients. There growing need for new inhibitors which encourages us to conduct this research. In work, synthesis vitro study four 4-bromophenethylbenzamides 9a-d were carried out. showed that targeted compounds exhibit acceptable activity against CETP, where compound 9a has % inhibition 40.7 at 10 µM concentration. It was presence oxy group both 9c enhances their could be attributed Hydrogen-bond formation with amino acid residues binding site.